GlassScriptPhysician profile
Celeste N Farmer
NPI 1851856876
$3,151.63
in general payments reported to CMS, 2019-2025
33 companies · $841 in 2025
The $841 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $690 · 2022: $314 · 2023: $556 · 2024: $751 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $634.77 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $279.89 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $254.38 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $215.13 | 2022-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $205.01 | 2024-2025 | Voquezna |
| Abbvie INC. | $147.52 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $137.15 | 2021 | |
| Pfizer INC. | $124.40 | 2021-2025 | |
| Exact Sciences Corporation | $119.06 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $99.67 | 2021-2024 | |
| Glaxosmithkline, LLC. | $98.88 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.94 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $84.81 | 2021 | |
| Corcept Therapeutics | $84.74 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.18 | 2021-2024 | Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.75 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $56.15 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $51.46 | 2023-2024 | Rexulti |
| Lundbeck LLC | $34.05 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $33.61 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $29.72 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $28.38 | 2024 | Crysvita |
| E.R. Squibb & Sons, L.L.C. | $24.71 | 2021-2023 | Eliquis |
| Scpharmaceuticals INC. | $22.81 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.80 | 2022 | |
| Seqirus USA INC | $19.36 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.26 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.48 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.97 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.33 | 2025 | |
| Abbott Laboratories | $13.36 | 2023 | Freestyle Libre |
| Astellas Pharma US INC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.